JP3576200B2 - Whitening cosmetics - Google Patents
Whitening cosmetics Download PDFInfo
- Publication number
- JP3576200B2 JP3576200B2 JP09531994A JP9531994A JP3576200B2 JP 3576200 B2 JP3576200 B2 JP 3576200B2 JP 09531994 A JP09531994 A JP 09531994A JP 9531994 A JP9531994 A JP 9531994A JP 3576200 B2 JP3576200 B2 JP 3576200B2
- Authority
- JP
- Japan
- Prior art keywords
- extract
- pigmentation
- amount
- enzyme
- preparation example
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000002537 cosmetic Substances 0.000 title claims description 44
- 230000002087 whitening effect Effects 0.000 title claims description 43
- 239000000284 extract Substances 0.000 claims description 61
- 230000007935 neutral effect Effects 0.000 claims description 19
- 235000007164 Oryza sativa Nutrition 0.000 claims description 14
- 235000009566 rice Nutrition 0.000 claims description 14
- 238000000605 extraction Methods 0.000 claims description 12
- 239000007787 solid Substances 0.000 claims description 11
- 235000013339 cereals Nutrition 0.000 claims description 8
- 240000007594 Oryza sativa Species 0.000 claims 1
- 239000000203 mixture Substances 0.000 description 66
- 238000009472 formulation Methods 0.000 description 55
- 238000002360 preparation method Methods 0.000 description 50
- 239000006071 cream Substances 0.000 description 49
- 239000000243 solution Substances 0.000 description 41
- 208000012641 Pigmentation disease Diseases 0.000 description 39
- 102000004190 Enzymes Human genes 0.000 description 38
- 108090000790 Enzymes Proteins 0.000 description 38
- 229940088598 enzyme Drugs 0.000 description 38
- 230000019612 pigmentation Effects 0.000 description 36
- 230000000694 effects Effects 0.000 description 24
- 238000011156 evaluation Methods 0.000 description 22
- 239000000047 product Substances 0.000 description 21
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 18
- 230000000052 comparative effect Effects 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 16
- 239000007788 liquid Substances 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 241000209094 Oryza Species 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 11
- 239000002609 medium Substances 0.000 description 11
- 239000013040 bath agent Substances 0.000 description 10
- 230000002401 inhibitory effect Effects 0.000 description 10
- 239000008213 purified water Substances 0.000 description 10
- 239000003788 bath preparation Substances 0.000 description 9
- 230000007515 enzymatic degradation Effects 0.000 description 9
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 9
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 239000003921 oil Substances 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 239000007857 degradation product Substances 0.000 description 7
- VJNCICVKUHKIIV-UHFFFAOYSA-N dopachrome Chemical compound O=C1C(=O)C=C2NC(C(=O)O)CC2=C1 VJNCICVKUHKIIV-UHFFFAOYSA-N 0.000 description 7
- 235000019198 oils Nutrition 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 102000003425 Tyrosinase Human genes 0.000 description 6
- 108060008724 Tyrosinase Proteins 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 238000000354 decomposition reaction Methods 0.000 description 6
- 235000019441 ethanol Nutrition 0.000 description 6
- 201000001441 melanoma Diseases 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 102000057297 Pepsin A Human genes 0.000 description 5
- 108090000284 Pepsin A Proteins 0.000 description 5
- 102000035195 Peptidases Human genes 0.000 description 5
- 108091005804 Peptidases Proteins 0.000 description 5
- 108090000631 Trypsin Proteins 0.000 description 5
- 102000004142 Trypsin Human genes 0.000 description 5
- 239000012046 mixed solvent Substances 0.000 description 5
- -1 pH adjusters Substances 0.000 description 5
- 229940111202 pepsin Drugs 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 239000012588 trypsin Substances 0.000 description 5
- 229940058015 1,3-butylene glycol Drugs 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 239000004365 Protease Substances 0.000 description 4
- 235000019437 butane-1,3-diol Nutrition 0.000 description 4
- 244000309466 calf Species 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000003925 fat Substances 0.000 description 4
- 235000019197 fats Nutrition 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 230000008099 melanin synthesis Effects 0.000 description 4
- 210000003470 mitochondria Anatomy 0.000 description 4
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 4
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 4
- 235000019834 papain Nutrition 0.000 description 4
- 235000019833 protease Nutrition 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 206010014970 Ephelides Diseases 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 208000003351 Melanosis Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000003906 humectant Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 210000004694 pigment cell Anatomy 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- 108010004032 Bromelains Proteins 0.000 description 2
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 108090000526 Papain Proteins 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 235000019835 bromelain Nutrition 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000000686 essence Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 229940055729 papain Drugs 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 210000002826 placenta Anatomy 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 235000013772 propylene glycol Nutrition 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000002123 temporal effect Effects 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- QIVUCLWGARAQIO-OLIXTKCUSA-N (3s)-n-[(3s,5s,6r)-6-methyl-2-oxo-1-(2,2,2-trifluoroethyl)-5-(2,3,6-trifluorophenyl)piperidin-3-yl]-2-oxospiro[1h-pyrrolo[2,3-b]pyridine-3,6'-5,7-dihydrocyclopenta[b]pyridine]-3'-carboxamide Chemical compound C1([C@H]2[C@H](N(C(=O)[C@@H](NC(=O)C=3C=C4C[C@]5(CC4=NC=3)C3=CC=CN=C3NC5=O)C2)CC(F)(F)F)C)=C(F)C=CC(F)=C1F QIVUCLWGARAQIO-OLIXTKCUSA-N 0.000 description 1
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- JRMXMUCILWKNNW-UHFFFAOYSA-N 1-butoxy-2-methylbenzene Chemical compound CCCCOC1=CC=CC=C1C JRMXMUCILWKNNW-UHFFFAOYSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- FUTGDWNFCMWSJT-UHFFFAOYSA-N 2,3-bis(14-methylpentadecanoyloxy)propyl 14-methylpentadecanoate Chemical compound CC(C)CCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCC(C)C)COC(=O)CCCCCCCCCCCCC(C)C FUTGDWNFCMWSJT-UHFFFAOYSA-N 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- LIFHMKCDDVTICL-UHFFFAOYSA-N 6-(chloromethyl)phenanthridine Chemical compound C1=CC=C2C(CCl)=NC3=CC=CC=C3C2=C1 LIFHMKCDDVTICL-UHFFFAOYSA-N 0.000 description 1
- 102000004400 Aminopeptidases Human genes 0.000 description 1
- 108090000915 Aminopeptidases Proteins 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 241001212017 Brana Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 102000005367 Carboxypeptidases Human genes 0.000 description 1
- 108010006303 Carboxypeptidases Proteins 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 108090001069 Chymopapain Proteins 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 239000004287 Dehydroacetic acid Substances 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 108010008488 Glycylglycine Proteins 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- AOMUHOFOVNGZAN-UHFFFAOYSA-N N,N-bis(2-hydroxyethyl)dodecanamide Chemical compound CCCCCCCCCCCC(=O)N(CCO)CCO AOMUHOFOVNGZAN-UHFFFAOYSA-N 0.000 description 1
- 241000772415 Neovison vison Species 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- VBIIFPGSPJYLRR-UHFFFAOYSA-M Stearyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)C VBIIFPGSPJYLRR-UHFFFAOYSA-M 0.000 description 1
- 241000270666 Testudines Species 0.000 description 1
- ISWQCIVKKSOKNN-UHFFFAOYSA-L Tiron Chemical compound [Na+].[Na+].OC1=CC(S([O-])(=O)=O)=CC(S([O-])(=O)=O)=C1O ISWQCIVKKSOKNN-UHFFFAOYSA-L 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 235000021302 avocado oil Nutrition 0.000 description 1
- 239000008163 avocado oil Substances 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- QMNOIORHZMRPLS-UHFFFAOYSA-N butan-1-ol;ethane-1,2-diol;propane-1,2-diol Chemical compound OCCO.CCCCO.CC(O)CO QMNOIORHZMRPLS-UHFFFAOYSA-N 0.000 description 1
- PLXUFYVBQPIQQH-UHFFFAOYSA-N butoxymethoxybenzene Chemical compound CCCCOCOC1=CC=CC=C1 PLXUFYVBQPIQQH-UHFFFAOYSA-N 0.000 description 1
- 229940067596 butylparaben Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- WOWHHFRSBJGXCM-UHFFFAOYSA-M cetyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+](C)(C)C WOWHHFRSBJGXCM-UHFFFAOYSA-M 0.000 description 1
- 229960002976 chymopapain Drugs 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000008406 cosmetic ingredient Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 235000019258 dehydroacetic acid Nutrition 0.000 description 1
- JEQRBTDTEKWZBW-UHFFFAOYSA-N dehydroacetic acid Chemical compound CC(=O)C1=C(O)OC(C)=CC1=O JEQRBTDTEKWZBW-UHFFFAOYSA-N 0.000 description 1
- 229940061632 dehydroacetic acid Drugs 0.000 description 1
- PGRHXDWITVMQBC-UHFFFAOYSA-N dehydroacetic acid Natural products CC(=O)C1C(=O)OC(C)=CC1=O PGRHXDWITVMQBC-UHFFFAOYSA-N 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229960000735 docosanol Drugs 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 229960004756 ethanol Drugs 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 229940043257 glycylglycine Drugs 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- WTFXARWRTYJXII-UHFFFAOYSA-N iron(2+);iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+2].[Fe+3].[Fe+3] WTFXARWRTYJXII-UHFFFAOYSA-N 0.000 description 1
- LDHBWEYLDHLIBQ-UHFFFAOYSA-M iron(3+);oxygen(2-);hydroxide;hydrate Chemical compound O.[OH-].[O-2].[Fe+3] LDHBWEYLDHLIBQ-UHFFFAOYSA-M 0.000 description 1
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- TYQCGQRIZGCHNB-JLAZNSOCSA-N l-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000010445 mica Substances 0.000 description 1
- 229910052618 mica group Inorganic materials 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 229940056211 paraffin Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 229940109850 royal jelly Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229940045920 sodium pyrrolidone carboxylate Drugs 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- HYRLWUFWDYFEES-UHFFFAOYSA-M sodium;2-oxopyrrolidine-1-carboxylate Chemical compound [Na+].[O-]C(=O)N1CCCC1=O HYRLWUFWDYFEES-UHFFFAOYSA-M 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 150000003445 sucroses Chemical class 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Images
Landscapes
- Cosmetics (AREA)
Description
【０００１】
【産業上の利用分野】
本発明は、美白化粧料に関する。さらに詳しくは、すぐれた美白効果を奏し、基礎化粧品をはじめ、メイクアップ化粧品、浴用剤などに好適に使用しうる美白化粧料に関する。
【０００２】
【従来の技術】
従来、美白効果を奏する化粧料の必要性が高まるにつれて種々の研究が行なわれ、各種美白化粧料が提案されている。しかしながら、従来の美白化粧料には、皮膚などに対する安全性や保存安定性に加え、とくにその美白効果を充分に満足するものがない。
【０００３】
【発明が解決しようとする課題】
そこで、本発明者らは、前記従来技術に鑑みて鋭意研究を重ねた結果、穀物や穀物の精製時に生じる残渣を中性媒体で抽出してえられる抽出物が培養色素細胞のチロジナーゼ活性を低下させ、メラニンの生成を抑制し、紫外線照射によって生じる色素沈着をも抑制するうえ、くすみ感も改善するといったすぐれた効果を奏することを見出し、本発明を完成するにいたった。
【０００４】
【課題を解決するための手段】
すなわち、本発明は、穀物の精製残渣である米糠を中性媒体で抽出してなる抽出物を配合したことを特徴とする美白化粧料に関する。
【０００５】
【作用および実施例】
本発明の美白化粧料は、前記したように、穀物の精製残渣である米糠を中性媒体で抽出してえられた抽出物を配合したものである。
【０００６】
本発明に用いられる穀物の精製残渣である米糠は、後述する中性媒体で抽出してえられる抽出物がよりすぐれた美白効果を奏するという点から好ましい。
【０００７】
前記穀物の精製残渣である米糠を中性媒体で抽出する際に用いられる溶媒としては、たとえば精製水などの水；エタノールなどの１価の低級アルコール類；オレイルアルコール、ステアリルアルコール、オクチルドデカノールなどの１価の高級アルコール類；エチレングリコール、プロピレングリコール、グリセリン、1,3-ブチレングリコールなどのポリオール類；アセトンなどのケトン類；酢酸エチルなどのエステル類；ヘキサン、クロロホルム、ベンゼンなどの炭化水素系溶剤などがあげられ、これらは単独でまたは２種以上を混合して用いることができる。これらのなかでは、化粧料への幅広い適用が可能であるという点から、精製水や、精製水と、エタノール、グリセリンおよび1,3-ブチレングリコールの１種または２種以上との混合溶媒が好ましい。
【０００８】
なお、前記混合溶媒を用いるばあいには、たとえば精製水とエタノールとの混合溶媒のばあいには、両者の容量比は１：１〜２５：１、精製水とグリセリンとの混合溶媒のばあいには、両者の容量比は１：１〜１５：１、精製水と１，３−ブチレングリコールとの混合溶媒のばあいには、両者の容量比は１：１〜１５：１であることが好ましい。
【０００９】
本発明において、中性媒体で穀物の精製残渣である米糠の抽出を行なう際には、米糠を含有した抽出溶液のｐＨが５〜９程度であればよく、前記溶媒をそのまま用いてもよいが、たとえば水酸化ナトリウム、炭酸ナトリウムなどのナトリウム塩、水酸化カリウムなどのカリウム塩などのアルカリ性調整剤や、たとえばクエン酸、塩酸、リン酸、硫酸などの酸性調整剤などを前記溶媒に配合し、目的とするｐＨとなるように調整することもできる。これら調整剤のなかでは、低濃度で目的とするｐＨとなるように調整することができるという点から、水酸化ナトリウム、炭酸ナトリウム、塩酸およびリン酸が好ましい。
【００１０】
前記抽出処理に要する時間は、用いる溶媒の種類、目的とするｐＨ、抽出温度などによって異なるので一概には決定することができないが、たとえばｐＨが５〜９のばあい、通常室温で６時間〜７日間程度、なかんづく１２〜４８時間程度であることが好ましい。なお、抽出温度は、好ましくは４〜４０℃程度、さらに好ましくは１０〜３０℃程度である。
【００１１】
かくしてえられた抽出物は、そのまま美白化粧料に配合してもよく、たとえば減圧下で濃縮して濃度を調整したのち配合してもよく、またたとえば凍結乾燥法やスプレイドライ法などによって粉末化したものを配合してもよい。
【００１２】
前記抽出物の配合量は、目的とする美白化粧料の種類などによって異なるので一概には決定することができないが、かかる配合量があまりにも少ないばあいには、該抽出物を配合したことによる美白効果が充分に発現されなくなる傾向があるので、美白化粧料１００ 部（重量部、以下同様）に対して固形分換算で０．０００５部以上、なかんづく０．００５ 部以上となるように調整することが好ましく、またあまりにも多いばあいには、該抽出物を美白化粧料に安定に配合することが技術的に困難となる傾向があるので、美白化粧料１００ 部に対して固形分換算で５部以下、なかんづく１部以下となるように調整することが好ましい。
【００１３】
さらに、前記抽出物を酵素で処理してえられる分解物を配合するばあいには、チロジナーゼ活性の低下、メラニン生成の抑制や、紫外線照射によって生じる色素沈着の抑制などの美白効果の発現がより大きいという点から好ましい。ただし、前記抽出物を酵素で処理してえられる分解物を配合するばあいは、本発明には含まれない。
【００１４】
前記酵素としては、たとえばアクチナーゼなどのアクチナーゼ類、ペプシンなどのペプシン類、トリプシン、キモトリプシンなどのトリプシン類、パパイン、キモパパインなどのパパイン類、グリシルグリシンペプチターゼ、カルボキシペプチターゼ、アミノペプチターゼなどのペプチターゼ類、ブロメラインなどの蛋白分解酵素などがあげられる。これらのなかでは、アクチナーゼと、ペプシン類、トリプシン類、パパイン類、ペプチターゼ類およびブロメラインから選ばれた蛋白分解酵素の少なくとも１種とを組合わせたものが、えられる分解物が配合された美白化粧料が保存安定性および安全性にすぐれるという点から好ましく、アクチナーゼとペプシンおよびトリプシンとの組合わせがとくに好ましい。
【００１５】
なお、２種類以上の酵素を用いて処理するばあいには、通常１回につき１種類の酵素が用いられる。
【００１６】
酵素処理を行なう際の１回あたりの酵素の使用量は、前記米糠を含有した中性の抽出溶液100 部に対して0.0005〜0.05部程度、なかんづく0.001 〜0.005 部程度であり、合計して0.003 〜0.015 部程度であることが、かかる酵素の作用効果の点で好ましい。
【００１７】
前記酵素処理に要する時間は、用いる酵素の種類や分解温度などによって異なるので一概には決定することができないが、１種類の酵素につき通常３０分間〜２４時間程度、なかんづく１〜４時間程度であることが好ましい。なお、前記例示した酵素の分解温度は約３０〜５０℃である。
【００１８】
また、酵素処理を行なう際には、抽出溶液のｐＨが用いる酵素の至適ｐＨとなるように調整すればよく、かかる抽出溶液のｐＨを調整するには、必要に応じて、たとえば前記抽出を行なう際に用いられる酸性調整剤やアルカリ性調整剤などを用いることができる。
【００１９】
かくしてえられた分解物は、そのまま美白化粧料に配合してもよく、たとえば減圧下で濃縮して濃度を調整したのち配合してもよく、またたとえば凍結乾燥法やスプレイドライ法によって粉末化したものを配合してもよい。
【００２０】
なお、えられた分解物を含む溶液は、皮膚への安全性の点からｐＨ４〜８に調整されることが好ましい。
【００２１】
前記分解物の配合量は、目的とする美白化粧料の種類などによって異なるので一概には決定することができないが、かかる配合量があまりにも少ないばあいには、該分解物を配合したことによる美白効果が充分に発現されなくなる傾向があるので、美白化粧料１００ 部に対して固形分換算で０．０００５部以上、なかんづく０．００５ 部以上となるように調整することが好ましく、またあまりにも多いばあいには、該分解物を美白化粧料に安定に配合することが技術的に困難となる傾向があるので、美白化粧料１００ 部に対して固形分換算で５部以下、なかんづく１部以下となるように調整することが好ましい。
【００２２】
本発明に用いられる抽出物や前記分解物は、培養色素細胞のチロジナーゼ活性の低下、メラニン生成の抑制効果や紫外線照射によって生じる色素沈着の抑制効果を同時に奏するものであり、かかる抽出物や分解物が配合された美白化粧料を用いたばあいには、メラニンの蓄積によるシミ、ソバカスなどの発現が抑制され、くすみ感が改善された白く美しい肌が維持される。
【００２３】
本発明の美白化粧料は、前記したように、穀物の精製残渣である米糠を中性媒体で抽出してえられた抽出物が配合されたものであるが（該抽出物のかわりに該抽出物を酵素で処理してえられた分解物を使用することができるが、これは本発明の美白化粧料には含まれない）、本発明においては、これらのほかにも、たとえば一般に化粧料に用いられている賦形剤、香料などをはじめ、油脂類、界面活性剤、保湿剤、美白剤、ｐＨ調整剤、増粘剤、防腐剤、酸化防止剤、紫外線吸収剤、顔料、洗浄剤、乾燥剤、乳化剤などの各種化粧料成分を美白化粧料に適宜配合することができる。
【００２４】
前記油脂類としては、一般に化粧料に汎用されている、たとえば流動パラフィン、パラフィン、セタノール、アボカド油、オリーブ油、ホホバ油、ヤシ油などの植物性油脂；牛脂、豚脂、馬脂、タートル油、ミンク油、パーセリン油、スクワランなどの動物性油脂；メチルポリシロキサン、ベヘニルアルコール、トリカプリルカプリン酸グリセリル、トリオクタン酸グリセリル、トリイソパルミチン酸グリセリン、シリコーンオイルなどの合成油脂などがあげられる。
【００２５】
前記界面活性剤としては、たとえばラウリル硫酸ナトリウム、ラウリル硫酸トリエタノールアミン、ラウリン酸ジエタノールアミドなどの陰イオン性界面活性剤；ステアリルトリメチルアンモニウムクロライド、セチルトリメチルアンモニウムクロライド、塩化ベンザルコニウムなどの陽イオン性界面活性剤；グリセリルモノステアレート、ソルビタンモノステアレート、ポリオキシエチレン（２０）ソルビタンモノステアレート、ポリオキシエチレン硬化ヒマシ油、ショ糖エステル、脂肪酸アミドなどの非イオン性界面活性剤などがあげられる。
【００２６】
前記保湿剤としては、たとえばグリセリン、プロピレングリコール、１，３−ブチレングリコール、ピロリドンカルボン酸ソーダ、パントテテイン−Ｓ−スルホン酸塩などの合成保湿剤；ヒアルロン酸、コラーゲン、エラスチン、胎盤抽出液、ローヤルゼリー、微生物発酵液、たとえばキチン、キトサン、ペクチンなどや、その他の植物や動物由来の抽出液などの天然保湿液などがあげられる。
【００２７】
前記美白剤としては、たとえばコウジ酸、アスコルビン酸、アルブチン、胎盤抽出液やこれらの誘導体などのほかにも、その他の植物や動物由来の抽出液などがあげられる。
【００２８】
前記ｐＨ調整剤としては、たとえばクエン酸、クエン酸ナトリウムなどの有機酸およびその塩類などがあげられる。
【００２９】
前記増粘剤としては、たとえばカルボキシメチルセルロース、ヒドロキシメチルセルロース、ヒドロキシエチルセルロース、カルボキシビニルポリマー、ポリビニルアルコール、トラガントガム、アルギン酸ナトリウム、カラギーナンなどがあげられる。
【００３０】
前記防腐剤としては、たとえばメチルパラベン、エチルパラベン、プロピルパラベン、ブチルパラベンなどのパラオキシ安息香酸エステル、フェノキシエタノール、エタノール、デヒドロ酢酸などがあげられる。
【００３１】
前記酸化防止剤としては、たとえばビタミンＥ、ブチルオキシトルエン（ＢＨＴ）、ブチルオキシアニゾール（ＢＨＡ）などがあげられる。
【００３２】
前記顔料としては、たとえばベンガラ、黄酸化鉄、黒酸化鉄、酸化チタン、ナイロンパウダー、セリサイト、マイカ、タルクなどがあげられる。
【００３３】
前記洗浄剤としては、たとえばラウリル硫酸ナトリウムなどがあげられる。
【００３４】
前記乳化剤としては、たとえば大豆レシチン油などがあげられる。
【００３５】
前記賦形剤としては、たとえば硫酸ナトリウムなどがあげられる。
【００３６】
これら各化粧料成分の配合量は、目的とする美白化粧料の用途などにより異なるので一概には決定することができず、用途に応じて適宜調整されることが好ましい。
【００３７】
本発明の美白化粧料の形態は任意であり、とくに限定されるものではないが、本発明の美白化粧料は、肌のくすみやシミ、ソバカスの発現を防ぎ、若々しく健康で、くすみ感が改善された白く美しい肌の状態を維持するなどのすぐれた性質を有するので、たとえばクリーム、乳液、ローション、エッセンス、洗顔料、パックなどの基礎化粧品、口紅、ファンデーション、リキッドファンデーション、プレスパウダーなどのメイクアップ化粧品、ボディーソープ、石鹸などのトイレタリー製品などとして用いることができる。
【００３８】
さらに、前記抽出物や分解物、およびこれらの乾燥粉末を湯に投入したばあいには、経皮吸収によって肌の状態の向上に効果があることから、美白化粧料は、浴用剤などとしても使用することができる。このように美白化粧料を浴用剤として用いるばあいには、前記抽出物や分解物の美白化粧料への配合量は、かかる抽出物や分解物が奏する肌の状態の向上効果を考慮すると、美白化粧料100部に対して抽出物または分解物の固形分換算で0.0005〜5.0部、なかんづく0.001〜0.1部であることが好ましい。なお、前記浴用剤を用いるばあい、該浴用剤の使用量は、通常湯200リットルに対して浴用剤が５〜50ｇ程度となるように調整することが好ましい。
【００３９】
つぎに本発明の美白化粧料を実施例に基づいてさらに詳細に説明するが、本発明はかかる実施例のみに限定されるものではない。
【００４０】
調製例１（米中性抽出物の製造）
米２００ ｇを精製水８００ｍｌ に加え、０．１ Ｎ水酸化ナトリウム水溶液にてｐＨを６．０ 〜８．０ に調整し、室温下で約２４時間浸漬して抽出し、抽出液（固形分含量：約１．５ 重量％）約４８０ｍｌ をえた。
【００４１】
調製例２（米中性抽出物の酵素分解物の製造）
調製例１でえられた抽出液に、アクチナーゼ（至適ｐＨ８．０ ）５ｍｇを添加して３０〜４０℃で１〜２時間かけて処理を行ない、つぎにペプシン（至適ｐＨ２．０ ）５ｍｇを添加して３０〜４０℃で１〜２時間かけて処理を行ない、最後にトリプシン（至適ｐＨ８．０ ）５ｍｇを添加して３０〜４０℃で１〜２時間かけて処理を行なった。
【００４２】
なお、各酵素を添加する際には、抽出液が各酵素の至適ｐＨとなるように調整した。
【００４３】
これをろ過して淡黄色透明の酵素分解物溶液（固形分含量：約２．０ 重量％）約２５０ｍｌ をえた。
【００４４】
調製例３（米糠中性抽出物の製造）
調製例１において、米のかわりに米糠を用いたほかは調製例１と同様にして抽出液（固形分含量：約１．５ 重量％）約４８０ｍｌ をえた。
【００４５】
調製例４（米糠中性抽出物の酵素分解物の製造）
調製例２において、調製例１でえられた抽出液のかわりに調製例３でえられた抽出液を用いたほかは調製例２と同様にして淡黄色透明の酵素分解物溶液（固形分含量：約２．０ 重量％）約２５０ｍｌ をえた。
【００４６】
調製例５（米糠中性抽出物の酵素分解物の製造）
調製例４において、ペプシンのかわりにパパイン（至適ｐＨ７．０ ）を用いたほかは調製例４と同様にして淡黄色透明の酵素分解物溶液（固形分含量：約２．０ 重量％）約２５０ｍｌ をえた。
【００４７】
調製例６（ふすま中性抽出物の酵素分解物の製造）
ふすま２００ ｇを精製水８００ｍｌ に加え、０．１ Ｎ塩酸にてｐＨを６．０ 〜８．０ に調整し、室温下で約２４時間浸漬して抽出し、抽出液約４８０ｍｌ をえた。
【００４８】
えられた抽出液にアクチナーゼ、ペプシン、トリプシン各１０ｍｇを順次添加したほかは調製例４と同様にして処理した。
【００４９】
これをろ過して淡黄色透明の酵素分解物溶液（固形分含量：約２．０ 重量％）約３００ｍｌ をえた。
【００５０】
調製例７（米糠中性抽出物の凍結乾燥処理物の製造）
調製例３でえられた抽出液１００ ｇを濃縮し、ついで真空凍結乾燥して抽出物の乾燥粉末約１．５ ｇをえた。
【００５１】
調製例８（米糠中性抽出物の酵素分解物のスプレイドライ処理物の製造）
調製例４でえられた酵素分解物溶液２５０ ｇをスプレイドライ処理して分解物の乾燥粉末約５ｇをえた。
【００５２】
つぎに、調製例３でえられた抽出液および調製例４でえられた酵素分解物溶液を用い、以下に示す試験を行なった。
【００５３】
試験例１（細胞内チロジナーゼ活性抑制作用）
培養Ｂ１６マウスメラノーマ細胞を、９６穴マイクロプレート（ＣＯＲＮＩＮＧ社）に８０００個／穴播種し、３容量％仔牛血清含有イーグル最少必須培地（ＭＥＭ）で３７℃、５％ＣＯ２ の条件下で２４時間プレ培養したのち、調製例３でえられた抽出液もしくは調製例４でえられた酵素分解物溶液を５容量％または１０容量％添加した３容量％仔牛血清含有イーグルＭＥＭと交換し、さらに３７℃、５％ＣＯ２ の条件下で４８時間培養した。
【００５４】
つぎに培地を除去してＰＢＳ（−）で洗浄後、０．１ Ｎリン酸緩衝液および５ｍモルＬ−ドーパを添加して３７℃で１時間インキュベーションを行ない、ドーパクロムの生成量をマイクロプレートリーダー（ＢＩＯ ＲＡＤ社）を用いて測定した。
【００５５】
抽出液の添加量または酵素分解物溶液の添加量とドーパクロムの生成量との関係を図１（調製例３でえられた抽出液を用いたばあい）および図３（調製例４でえられた酵素分解物溶液を用いたばあい）のグラフに示す。なお、図１および図３のグラフは、抽出液または酵素分解物溶液をまったく添加しなかったばあいのドーパクロムの生成量を１００ ％として表わしたものである。
【００５６】
また、抽出液の添加量または酵素分解物溶液の添加量と、培養Ｂ１６マウスメラノーマ細胞の細胞活性を表わすＭＴＴ還元法によるミトコンドリア内の還元型ニコチンアミドアデニシンジヌクレオチド（以下、ＮＡＤＨという）の量との関係を図２（調製例３でえられた抽出液を用いたばあい）および図４（調製例４でえられた酵素分解物溶液を用いたばあい）のグラフに示す。なお、図２および図４のグラフは、抽出液または酵素分解物溶液をまったく添加しなかったばあいのＭＴＴ還元法によるミトコンドリア内のＮＡＤＨの量を１００ ％として表わしたものである。
【００５７】
図１および図２に示されたグラフから明らかなように、調製例３でえられた抽出液は、その添加量が増加するにつれて、培養Ｂ１６マウスメラノーマ細胞の細胞活性をほとんど阻害することなく、ドーパクロムの生成量を低下させ、細胞内チロジナーゼ活性を抑制することがわかる。
【００５８】
また、図３および図４に示されたグラフから明らかなように、調製例４でえられた酵素分解物溶液は、その添加量が増加するにつれて、培養Ｂ１６マウスメラノーマ細胞の細胞活性を阻害することなく、ドーパクロムの生成量をいちじるしく低下させ、細胞内チロジナーゼ活性を顕著に抑制することがわかる。
【００５９】
試験例２（メラニン生成抑制作用）
培養Ｂ１６マウスメラノーマ細胞を内径６０ｍｍのシャーレ（ＣＯＲＮＩＮＧ社）に１００００ 個播種し、５容量％仔牛血清含有イーグルＭＥＭで３７℃、５％ＣＯ２ の条件下で２日間プレ培養したのち、調製例４でえられた酵素分解物溶液を５容量％または１０容量％添加した３容量％仔牛血清含有イーグルＭＥＭと交換し、さらに３７℃、５％ＣＯ２ の条件下で３日間培養した。
【００６０】
つぎに培地を除去してＰＢＳ（−）で洗浄後、トリプシンで細胞を剥離し、細胞数を計測すると同時に１０％ジメチルスルホキサイド含有１Ｎ水酸化ナトリウム水溶液で高温加熱処理を行ない、メラニンを溶出させてその溶液を可変分光光度計（（株）日立製作所製、Ｕ−２０００）を用いてメラニンの生成量を測定した。
【００６１】
酵素分解物溶液の添加量と細胞１０６ 個あたりのメラニンの生成量との関係を図５のグラフに示す。なお、図５のグラフは、酵素分解物溶液をまったく添加しなかったばあいのメラニンの生成量を１００ ％として表わしたものである。
【００６２】
図５に示されたグラフから明らかなように、調製例４でえられた酵素分解物溶液は、その添加量が増加するにつれて、培養Ｂ１６マウスメラノーマ細胞におけるメラニンの生成をいちじるしく抑制することがわかる。
【００６３】
試験例３（皮膚に対する安全性）
調製例２および４でえられた酵素分解物溶液を用い、ヒトの皮膚に対する安全性をクローズドパッチテストを行なって調べた。
【００６４】
無作為に抽出した年齢２０〜７０歳の健常な成人男女２０名を被験者とし、調製例２または調製例４でえられた酵素分解物溶液０．２ｍｌ を各被験者の上腕部皮膚上にそれぞれ塗布し、その上部からヒトパッチテスト用絆創膏（リバーテープ（株）製）を貼付した。
【００６５】
また、対照として、前記ヒトパッチテスト用絆創膏を、その円形布地部が酵素分解物溶液を塗布した部位にそれぞれ並行するように貼付した。
【００６６】
４８時間経過後、各ヒトパッチテスト用絆創膏を取り除き、酵素分解物溶液を塗布した部位および対照部位の皮膚の症状を目視にて観察し、日本パッチテスト研究会によるクローズドパッチテストの評価基準に基づいて評価した。
【００６７】
その結果、調製例２および４でえられた酵素分解物溶液のヒトの皮膚に対する一時刺激はまったく認められず、これら酵素分解物溶液がいずれも皮膚に対する安全性にすぐれたものであることがわかる。
【００６８】
処方例１〜１２および比較処方例１〜３
【００６９】
処方例２（クリーム）
調製例１でえられた抽出液のかわりに調製例２でえられた酵素分解物溶液を用いたほかは処方例１と同様にしてクリームを調製した。
【００７０】
処方例３（クリーム）
調製例１でえられた抽出液のかわりに調製例３でえられた抽出液を用いたほかは処方例１と同様にしてクリームを調製した。
【００７１】
処方例４（クリーム）
調製例１でえられた抽出液のかわりに調製例４でえられた酵素分解物溶液を用いたほかは処方例１と同様にしてクリームを調製した。
【００７２】
【００７３】
【００７４】
【００７５】
【００７６】
【００７７】
【００７８】
【００７９】
【００８０】
比較処方例１（クリーム）
調製例１でえられた抽出液のかわりに精製水を用いたほかは処方例１と同様にしてクリームを調製した。
【００８１】
比較処方例２（浴用剤）
調製例７でえられた凍結乾燥処理物のかわりにマンニット（Ｄ−マンニトール）を用いたほかは処方例１０と同様にして浴用剤を調製した。
【００８２】
比較処方例３（リキッドファンデーション）
調製例４でえられた酵素分解物溶液のかわりに精製水を用いたほかは処方例１２と同様にしてリキッドファンデーションを調製した。
【００８３】
参考例１
処方例１および比較処方例１でえられたクリームを用い、紫外線照射による色素沈着に対する抑制作用を調べた。
【００８４】
無作為に抽出した年齢２０〜３５歳の健常な成人男性１０名を被験者とし、その前腕内側部に１ｃｍ×１ｃｍの紫外線照射部を２箇所設定した。ＵＶ−Ｂランプ（（株）東芝製、ＦＬ２０−ＳＥ）を用い、あらかじめ測定しておいた各被験者の最小紅斑量（ＭＥＤ）に相当する量の紫外線を１日１回（朝）、３日間連続して照射した。
【００８５】
紫外線照射開始日から３０日間連続して、紫外線照射期間（最初の３日間）は紫外線照射直後および夕刻の１日２回、紫外線照射期間経過後（４日目以降）は朝および夕刻の１日２回、各紫外線照射部に処方例１でえられたクリームおよび比較処方例１でえられたクリームを約０．０１ｇずつ塗布した。
【００８６】
各被験者の紫外線照射部の色素沈着状態を紫外線照射開始日から５日間ごとに目視にて観察し、処方例１でえられたクリームを塗布したばあいの色素沈着抑制効果を以下の評価基準に基づいて評価した。
【００８７】
（評価基準）
Ａ：処方例１でえられたクリームを塗布した箇所では、色素沈着がほとんど認められない。
Ｂ：処方例１でえられたクリームを塗布した箇所では、比較処方例１でえられたクリームを塗布した箇所と比べて色素沈着が明らかに少ない。
Ｃ：処方例１でえられたクリームを塗布した箇所では、比較処方例１でえられたクリームを塗布した箇所と比べて色素沈着が少ない。
Ｄ：処方例１でえられたクリームを塗布した箇所では、比較処方例１でえられたクリームを塗布した箇所と比べて色素沈着がやや少ない。
【００８８】
紫外線照射開始日から５日間ごとの色素沈着状態の評価結果を、被験者１０名を１００ ％としたときのＡ〜Ｄ各評価を下した人数の割合で表わし、各評価の占有率の変化を図６のグラフに示した。
【００８９】
参考例２
参考例１において、処方例１でえられたクリームのかわりに処方例２でえられたクリームを用いたほかは参考例１と同様にして各被験者の紫外線照射部の色素沈着状態を評価した。
【００９０】
紫外線照射開始日から５日間ごとの色素沈着状態の評価結果を、参考例１と同様にして図７のグラフに示した。
【００９１】
なお、参考例１および２において、処方例１および２でえられたクリームを塗布した際に、皮膚に異常などが生じた被験者は１名もなかった。
【００９２】
また、処方例１および２でえられたクリームは、３０日間でその状態に変化が生じることはなかった。
【００９３】
図６および図７に示された結果から明らかなように、処方例１でえられたクリームおよび処方例２でえられたクリームのいずれを用いたばあいであっても、紫外線照射開始日から日数が経過するにつれて、比較処方例１でえられたクリームを用いたばあいとの色素沈着に対する抑制作用の差が大きくなっており、処方例１および２でえられたクリームがすぐれた色素沈着抑制効果を奏するものであることがわかる。
【００９４】
さらに、図６のグラフと図７のグラフとを比べて、処方例２でえられたクリームを用いたばあいには、色素沈着がほとんど認められないＡ評価の占有率がさらに高いことから、処方例２のクリームに配合された調製例２でえられた酵素分解物溶液がよりすぐれた色素沈着抑制作用を呈するものであることがわかる。
【００９５】
実施例１
参考例１において、処方例１でえられたクリームのかわりに処方例３でえられたクリームを用いたほかは参考例１と同様にして各被験者の紫外線照射部の色素沈着状態を評価した。
【００９６】
紫外線照射開始日から５日間ごとの色素沈着状態の評価結果を、参考例１と同様にして図８のグラフに示した。
【００９７】
参考例３
参考例１において、処方例１でえられたクリームのかわりに処方例４でえられたクリームを用いたほかは参考例１と同様にして各被験者の紫外線照射部の色素沈着状態を評価した。
【００９８】
紫外線照射開始日から５日間ごとの色素沈着状態の評価結果を、参考例１と同様にして図９のグラフに示した。
【００９９】
なお、実施例１および参考例３において、処方例３および４でえられたクリームを塗布した際に、皮膚に異常などが生じた被験者は１名もなかった。
【０１００】
また、処方例３および４でえられたクリームは、３０日間でその状態に変化が生じることはなかった。
【０１０１】
図８および図９に示された結果から明らかなように、処方例３でえられたクリームおよび処方例４でえられたクリームのいずれを用いたばあいであっても、紫外線照射開始日から日数が経過するにつれて、比較処方例１でえられたクリームを用いたばあいとの色素沈着に対する抑制作用の差が大きくなっており、処方例３および４でえられたクリームがすぐれた色素沈着抑制効果を奏するものであることがわかる。
【０１０２】
さらに、図８のグラフと図９のグラフとを比べて、処方例４でえられたクリームを用いたばあいには、色素沈着がほとんど認められないＡ評価の占有率がきわめて高いことから、処方例４のクリームに配合された調製例４でえられた酵素分解物溶液がきわめてすぐれた色素沈着抑制作用を呈するものであることがわかる。
【０１０３】
実施例２
処方例10および比較処方例２でえられた浴用剤を用い、入浴による皮膚の色素沈着に対する抑制作用を調べた。
【０１０４】
無作為に抽出した年齢３０〜６０歳の健常な成人男女２０名を被験者群とし、湯２００ リットルに対して各浴用剤２５ｇを溶解して１日１回、１ヵ月間入浴してもらったのち、各被験者群の腋下部の色素沈着状態を目視にて観察し、以下の評価基準に基づいて評価した。その結果を表１に示す。
【０１０５】
（評価基準）
Ａ：色素沈着がほとんどなくなった。
Ｂ：色素沈着が明らかに少なくなった。
Ｃ：浴用剤を使用する前よりも色素沈着が少なくなった。
Ｄ：浴用剤を使用する前とほとんど変化がない。
Ｅ：浴用剤を使用する前よりも色素沈着がかえって多くなった。
【０１０６】
【表１】
表１に示された結果から明らかなように、処方例１０でえられた浴用剤を用いたばあいには、色素沈着がほとんどなくなる〜少なくなることから、比較処方例２でえられた浴用剤がほとんど色素沈着を抑制することができないのに対して、処方例１０でえられた浴用剤がすぐれた色素沈着抑制効果を奏するものであることがわかる。
【０１０８】
なお、実施例２において、処方例10でえられた浴用剤を用いて入浴した際に、皮膚に異常などが生じた被験者は１名もなかった。
【０１０９】
また、処方例１０でえられた浴用剤は、１ヵ月間でその状態に変化が生じることはなかった。
【０１１０】
参考例４
処方例12および比較処方例３でえられたリキッドファンデーションを用い、くすみ感の改善効果を調べた。
【０１１１】
無作為に抽出した年齢２５〜３５歳の健常な成人女性４０名を被験者とし、各被験者の顔面右ほおに処方例１２でえられたリキッドファンデーションを、顔面左ほおに比較処方例３でえられたリキッドファンデーションを、１日１回、１ヵ月間にわたって通常の使用量（約０．１ ｇ）ずつ塗布したのち、左右のほおのくすみを目視にて観察して比較し、以下の評価基準に基づいて評価した。
【０１１２】
（評価基準）
Ａ：右ほおのほうがいちじるしくくすみが少なくなった。
Ｂ：右ほおのほうが明らかにくすみが少なくなった。
Ｃ：右ほおのほうが少しくすみが少なくなった。
Ｄ：左右のほおで差が認められない。
Ｅ：左ほおのほうが明らかにくすみが少なくなった。
【０１１３】
その結果、Ａ評価が１９名、Ｂ評価が２０名およびＣ評価が１名で、Ｄ評価およびＥ評価を下した被験者は１名もなく、処方例１２でえられたリキッドファンデーションを用いたばあいは、比較処方例３でえられたリキッドファンデーションを用いたばあいと比べてくすみが少なくなることから、処方例１２でえられたリキッドファンデーションがすぐれたくすみ感の改善効果を奏するものであることがわかる。
【０１１４】
なお、参考例４において、処方例12でえられたリキッドファンデーションを塗布した際に、皮膚に異常などが生じた被験者は１名もなかった。
【０１１５】
また、処方例１２でえられたリキッドファンデーションは、１ヵ月間でその状態に変化が生じることはなかった。
【０１１６】
【発明の効果】
穀物の精製残渣である米糠を中性媒体で抽出してえられた抽出物は、美白効果の指標となる培養色素細胞の細胞内チロジナーゼ活性に対して、細胞活性をほとんど阻害せずに低下させてメラニンの生成を抑制し、紫外線照射によって生じる色素沈着を抑制するといったすぐれた作用を同時に呈するものであるので、かかる抽出物が配合された本発明の美白化粧料は、メラニンの蓄積によるシミ、ソバカスの発現を抑制し、肌の状態を向上させ、くすみ感が改善された白く美しい肌を維持するという効果を奏する。
【０１１８】
また、本発明の美白化粧料は、前記のごとくすぐれた美白効果を奏するうえ、皮膚などに対する安全性や保存安定性にもすぐれるといった効果を奏する。
【図面の簡単な説明】
【図１】調製例３でえられた抽出液の添加量とドーパクロムの生成量との関係を示すグラフである。
【図２】調製例３でえられた抽出液の添加量とＭＴＴ還元法によるミトコンドリア内のＮＡＤＨの量との関係を示すグラフである。
【図３】調製例４でえられた酵素分解物溶液の添加量とドーパクロムの生成量との関係を示すグラフである。
【図４】調製例４でえられた酵素分解物溶液の添加量とＭＴＴ還元法によるミトコンドリア内のＮＡＤＨの量との関係を示すグラフである。
【図５】調製例４でえられた酵素分解物溶液の添加量と細胞１０６ 個あたりのメラニンの生成量との関係を示すグラフである。
【図６】処方例１でえられたクリームを塗布したばあいの色素沈着抑制効果の各評価の占有率の紫外線照射開始日からの経時変化を示すグラフである。
【図７】処方例２でえられたクリームを塗布したばあいの色素沈着抑制効果の各評価の占有率の紫外線照射開始日からの経時変化を示すグラフである。
【図８】処方例３でえられたクリームを塗布したばあいの色素沈着抑制効果の各評価の占有率の紫外線照射開始日からの経時変化を示すグラフである。
【図９】処方例４でえられたクリームを塗布したばあいの色素沈着抑制効果の各評価の占有率の紫外線照射開始日からの経時変化を示すグラフである。[0001]
[Industrial applications]
The present invention relates to a whitening cosmetic. More particularly, the present invention relates to a whitening cosmetic which has an excellent whitening effect and can be suitably used for basic cosmetics, makeup cosmetics, bath preparations and the like.
[0002]
[Prior art]
Conventionally, as the necessity of cosmetics having a whitening effect has increased, various studies have been conducted, and various whitening cosmetics have been proposed. However, none of the conventional whitening cosmetics fully satisfies the whitening effect, in addition to the safety and storage stability against the skin and the like.
[0003]
[Problems to be solved by the invention]
Therefore, the present inventors have conducted intensive studies in view of the above-mentioned conventional technology, and as a result, an extract obtained by extracting a residue generated during purification of cereals or grains with a neutral medium reduces the tyrosinase activity of cultured pigment cells. The present inventors have found that the present invention exerts an excellent effect of suppressing the production of melanin, suppressing the pigmentation caused by ultraviolet irradiation, and improving the dull feeling, thereby completing the present invention.
[0004]
[Means for Solving the Problems]
That is, the present invention providesRice branA whitening cosmetic comprising an extract obtained by extracting a whitening agent with a neutral medium.
[0005]
[Action and Examples]
As described above, the whitening cosmetic of the present invention is a refined residue of grain.Rice branIs extracted with a neutral medium.
[0006]
Refined residue of grain used in the present inventionRice branIs,rearDoes the extract obtained with the neutral medium described above have a better whitening effect?GoodGood.
[0007]
Refined residue of the grainRice branExamples of the solvent used when extracting with a neutral medium include water such as purified water; monohydric lower alcohols such as ethanol; monohydric higher alcohols such as oleyl alcohol, stearyl alcohol and octyldodecanol; Polyols such as ethylene glycol, propylene glycol, glycerin, and 1,3-butylene glycol; ketones such as acetone; esters such as ethyl acetate; and hydrocarbon solvents such as hexane, chloroform, and benzene. They can be used alone or in combination of two or more. Of these, purified water or a mixed solvent of purified water and one or more of ethanol, glycerin, and 1,3-butylene glycol is preferable, since it can be widely applied to cosmetics. .
[0008]
In the case where the mixed solvent is used, for example, in the case of a mixed solvent of purified water and ethanol, the volume ratio of the two is 1: 1 to 25: 1, and in the case of the mixed solvent of purified water and glycerin. In some cases, the volume ratio of the two is 1: 1 to 15: 1, and in the case of a mixed solvent of purified water and 1,3-butylene glycol, the volume ratio of the two is 1: 1 to 15: 1. Is preferred.
[0009]
In the present invention, the purification residue of cereals in a neutral mediumRice branWhen extractingRice branThe solvent may be used as it is as long as the pH of the extraction solution containing is about 5 to 9, and for example, alkalinity adjustment such as sodium salts such as sodium hydroxide and sodium carbonate and potassium salts such as potassium hydroxide. An agent or an acid adjuster such as citric acid, hydrochloric acid, phosphoric acid, sulfuric acid, or the like may be added to the solvent to adjust the pH to a desired value. Among these regulators, sodium hydroxide, sodium carbonate, hydrochloric acid, and phosphoric acid are preferable because they can be adjusted to have a desired pH at a low concentration.
[0010]
The time required for the extraction treatment cannot be unconditionally determined because it varies depending on the type of the solvent used, the target pH, the extraction temperature, and the like. However, for example, when the pH is 5 to 9, it is usually 6 hours at room temperature. It is preferably about 7 days, especially about 12 to 48 hours. The extraction temperature is preferably about 4 to 40C, more preferably about 10 to 30C.
[0011]
The extract thus obtained may be directly blended into a whitening cosmetic, for example, may be concentrated under reduced pressure to adjust the concentration, and then may be blended, or may be powdered by, for example, freeze-drying or spray-drying. You may mix.
[0012]
The amount of the extract is different depending on the type of the target whitening cosmetics and the like, and therefore cannot be determined unconditionally. Since the whitening effect tends not to be sufficiently exhibited, the content is adjusted so as to be 0.0005 parts or more, especially 0.005 parts or more in terms of solid content with respect to 100 parts (parts by weight, hereinafter the same) of the whitening cosmetic. When the amount is too large, it tends to be technically difficult to stably incorporate the extract into a whitening cosmetic. Therefore, the solid content is calculated based on 100 parts of the whitening cosmetic. It is preferable to adjust the amount to be 5 parts or less, especially 1 part or less.
[0013]
further,In the case of blending the extract obtained by treating the extract with an enzyme,Does whitening effect such as reduction of tyrosinase activity, suppression of melanin production and suppression of pigmentation caused by ultraviolet irradiation be greater?GoodGood.However, the case where a decomposed product obtained by treating the extract with an enzyme is added is not included in the present invention.
[0014]
Examples of the enzyme include actinases such as actinase, pepsins such as pepsin, trypsins such as trypsin and chymotrypsin, papains such as papain and chymopapain, peptidases such as glycylglycine peptidase, carboxypeptidase and aminopeptidase. And proteolytic enzymes such as bromelain. Among these, a combination of actinase and at least one proteinase selected from pepsins, trypsins, papains, peptidases and bromelain is used as a whitening cosmetic containing a decomposed product. The ingredients are preferred in that they have excellent storage stability and safety, and a combination of actinase with pepsin and trypsin is particularly preferred.
[0015]
Note that, 2When treating with more than one type of enzyme, one type of enzyme is usually used at a time.
[0016]
The amount of enzyme used per time when performing enzyme treatment is as described above.Rice branIs preferably about 0.0005 to 0.05 part, especially about 0.001 to 0.005 part, and about 0.003 to 0.015 part in total with respect to 100 parts of the neutral extraction solution containing .
[0017]
The time required for the enzyme treatment cannot be determined unconditionally because it differs depending on the type of enzyme used, the decomposition temperature, etc., but it is usually about 30 minutes to 24 hours, preferably about 1 to 4 hours, for one type of enzyme. Is preferred. The decomposition temperature of the above exemplified enzyme is about 30 to 50 ° C.
[0018]
When performing the enzyme treatment, the pH of the extraction solution may be adjusted to be the optimum pH of the enzyme to be used. To adjust the pH of the extraction solution, if necessary, for example, the extraction may be performed. An acid conditioner or an alkalinity conditioner used at the time of carrying out can be used.
[0019]
The decomposed product thus obtained may be directly incorporated into a whitening cosmetic, for example, may be concentrated and then adjusted under reduced pressure to adjust the concentration, or may be powdered by, for example, a freeze-drying method or a spray-drying method. You may mix things.
[0020]
The solution containing the obtained decomposed product is preferably adjusted to pH 4 to 8 from the viewpoint of safety on the skin.
[0021]
The amount of the decomposed product cannot be determined unequivocally because it differs depending on the type of the intended whitening cosmetic, but if the amount is too small, the amount of the decomposed product may be reduced. Since there is a tendency that the whitening effect does not sufficiently appear, it is preferable to adjust the amount to be 0.0005 parts or more, especially 0.005 parts or more in terms of solid content with respect to 100 parts of the whitening cosmetic. If the amount is too large, it tends to be technically difficult to stably incorporate the decomposed product into a whitening cosmetic. Therefore, based on 100 parts of the whitening cosmetic, the solid content is 5 parts or less, especially 1 part. It is preferable to adjust so as to be as follows.
[0022]
Extract used in the present inventionAnd saidThe degraded product simultaneously reduces the tyrosinase activity of cultured pigment cells, suppresses melanin production, and suppresses pigmentation caused by ultraviolet irradiation, and is combined with such extracts and degraded products.BeautyWhen a white cosmetic is used, the appearance of spots and freckles due to the accumulation of melanin is suppressed, and white and beautiful skin with an improved dullness is maintained.
[0023]
As described above, the whitening cosmetic of the present invention is a refined residue of grain.Rice branIs extracted with a neutral medium, and an extract obtained by mixing the extract with an enzyme can be used instead of the extract. This is not included in the whitening cosmetic of the present invention). In the present invention, in addition to these, for example, excipients and fragrances generally used in cosmetics, oils and fats, surfactants Various cosmetic ingredients such as humectants, whitening agents, pH adjusters, thickeners, preservatives, antioxidants, ultraviolet absorbers, pigments, detergents, desiccants, emulsifiers, etc., are appropriately blended into whitening cosmetics. Can be.
[0024]
Examples of the fats and oils include vegetable fats and oils commonly used in cosmetics, such as liquid paraffin, paraffin, cetanol, avocado oil, olive oil, jojoba oil, and coconut oil; beef tallow, lard, horse fat, turtle oil, and the like. Animal fats and oils such as mink oil, parserin oil, and squalane; and synthetic fats and oils such as methylpolysiloxane, behenyl alcohol, glyceryl tricaprylcaprate, glyceryl trioctanoate, glyceryl triisopalmitate, and silicone oil.
[0025]
Examples of the surfactant include anionic surfactants such as sodium lauryl sulfate, triethanolamine lauryl sulfate, and diethanolamide laurate; and cationic surfactants such as stearyltrimethylammonium chloride, cetyltrimethylammonium chloride, and benzalkonium chloride. Surfactants: Nonionic surfactants such as glyceryl monostearate, sorbitan monostearate, polyoxyethylene (20) sorbitan monostearate, polyoxyethylene hydrogenated castor oil, sucrose esters, and fatty acid amides. .
[0026]
Examples of the humectant include synthetic humectants such as glycerin, propylene glycol, 1,3-butylene glycol, sodium pyrrolidone carboxylate, pantothetein-S-sulfonate; hyaluronic acid, collagen, elastin, placenta extract, royal jelly, Microbial fermented liquids, for example, chitin, chitosan, pectin and the like, and natural moisturizing liquids such as extracts derived from other plants and animals, etc.
[0027]
Examples of the whitening agent include kojic acid, ascorbic acid, arbutin, placenta extract, derivatives thereof, and the like, as well as other plant and animal-derived extracts.
[0028]
Examples of the pH adjuster include organic acids such as citric acid and sodium citrate and salts thereof.
[0029]
Examples of the thickener include carboxymethyl cellulose, hydroxymethyl cellulose, hydroxyethyl cellulose, carboxyvinyl polymer, polyvinyl alcohol, tragacanth gum, sodium alginate, carrageenan, and the like.
[0030]
Examples of the preservative include paraoxybenzoic acid esters such as methylparaben, ethylparaben, propylparaben, and butylparaben, phenoxyethanol, ethanol, and dehydroacetic acid.
[0031]
Examples of the antioxidant include vitamin E, butyloxytoluene (BHT), butyloxyanisole (BHA), and the like.
[0032]
Examples of the pigment include red iron oxide, yellow iron oxide, black iron oxide, titanium oxide, nylon powder, sericite, mica, and talc.
[0033]
Examples of the detergent include sodium lauryl sulfate.
[0034]
Examples of the emulsifier include soybean lecithin oil.
[0035]
Examples of the excipient include sodium sulfate.
[0036]
Since the amount of each of these cosmetic components varies depending on the intended use of the whitening cosmetic, it cannot be unconditionally determined, and is preferably adjusted appropriately according to the application.
[0037]
The form of the whitening cosmetic of the present invention is optional and not particularly limited, but the whitening cosmetic of the present invention prevents the appearance of dullness, spots and freckles on the skin, and is youthful, healthy and dull. Has excellent properties such as maintaining an improved white and beautiful skin condition, such as creams, emulsions, lotions, essences, facial cleansers, basic cosmetics such as packs, lipsticks, foundations, liquid foundations, press powders, etc. It can be used as toiletries such as makeup cosmetics, body soaps and soaps.
[0038]
Furthermore, when the extract or the decomposed product, and the dry powder thereof are put into hot water, it is effective in improving skin condition by transdermal absorption., BeautyWhite cosmetics can also be used as bath agents and the like. like thisBeautyWhen a white cosmetic is used as a bath agent, the amount of the extract or the decomposed product in the whitening cosmetic is determined in consideration of the effect of improving the skin condition of the extract or the decomposed product. The amount is preferably 0.0005 to 5.0 parts, more preferably 0.001 to 0.1 part, in terms of the solid content of the extract or the decomposition product with respect to 100 parts. When the bath agent is used, the amount of the bath agent is preferably adjusted so that the bath agent is usually about 5 to 50 g per 200 liters of hot water.
[0039]
Next, the whitening cosmetic of the present invention will be described in more detail based on examples, but the present invention is not limited to only these examples.
[0040]
Preparation Example 1 (Production of neutral extract of rice)
200 g of rice is added to 800 ml of purified water, the pH is adjusted to 6.0 to 8.0 with a 0.1 N aqueous solution of sodium hydroxide, and the mixture is immersed and extracted at room temperature for about 24 hours. (Content: about 1.5% by weight) about 480 ml was obtained.
[0041]
Preparation Example 2 (Production of enzymatic degradation product of rice neutral extract)
5 mg of actinase (optimal pH 8.0) was added to the extract obtained in Preparation Example 1 and the mixture was treated at 30 to 40 ° C. for 1 to 2 hours, and then 5 mg of pepsin (optimal pH 2.0) was added. Was added, and the treatment was carried out at 30 to 40 ° C. for 1 to 2 hours. Finally, 5 mg of trypsin (optimum pH 8.0) was added, and the treatment was carried out at 30 to 40 ° C. for 1 to 2 hours.
[0042]
In addition, when adding each enzyme, the extract was adjusted so that it might become the optimal pH of each enzyme.
[0043]
This was filtered to obtain about 250 ml of a pale yellow transparent enzyme decomposition product solution (solid content: about 2.0% by weight).
[0044]
Preparation Example 3 (Production of rice bran neutral extract)
About 480 ml of an extract (solid content: about 1.5% by weight) was obtained in the same manner as in Preparation Example 1, except that rice bran was used instead of rice.
[0045]
Preparation Example 4 (Production of enzymatic degradation product of rice bran neutral extract)
In Preparation Example 2, a pale yellow transparent enzymatic degradation solution (solid content) was prepared in the same manner as in Preparation Example 2, except that the extract obtained in Preparation Example 3 was used instead of the extract obtained in Preparation Example 1. : About 2.0% by weight).
[0046]
Preparation Example 5 (Production of enzymatically degraded rice bran neutral extract)
In Preparation Example 4, a pale yellow transparent enzymatic degradation product solution (solid content: about 2.0% by weight) was prepared in the same manner as in Preparation Example 4, except that papain (optimal pH 7.0) was used instead of pepsin. 250 ml were obtained.
[0047]
Preparation Example 6 (Production of enzymatic degradation product of bran neutral extract)
200 g of bran was added to 800 ml of purified water, the pH was adjusted to 6.0 to 8.0 with 0.1 N hydrochloric acid, and the mixture was immersed and extracted at room temperature for about 24 hours to obtain about 480 ml of an extract.
[0048]
The extract was treated in the same manner as in Preparation Example 4 except that actinase, pepsin and trypsin (10 mg each) were sequentially added to the obtained extract.
[0049]
This was filtered to obtain about 300 ml of a pale yellow transparent enzyme decomposition product solution (solid content: about 2.0% by weight).
[0050]
Preparation Example 7 (Production of freeze-dried rice bran neutral extract)
100 g of the extract obtained in Preparation Example 3 was concentrated and then freeze-dried in vacuo to obtain about 1.5 g of a dry powder of the extract.
[0051]
Preparation Example 8 (Production of spray-dried product of enzymatic degradation product of rice bran neutral extract)
250 g of the enzyme hydrolyzate solution obtained in Preparation Example 4 was spray-dried to obtain about 5 g of a dry powder of the hydrolyzate.
[0052]
Next, the following test was carried out using the extract obtained in Preparation Example 3 and the enzyme hydrolyzate solution obtained in Preparation Example 4.
[0053]
Test Example 1 (inhibition of intracellular tyrosinase activity)
Cultured B16 mouse melanoma cells were seeded at 8000 cells / well in a 96-well microplate (CORNING), and incubated at 37 ° C., 5% CO 2 in Eagle's minimum essential medium (MEM) containing 3% by volume of calf serum.2After pre-culturing for 24 hours under the conditions described above, Eagle MEM containing 3% by volume of calf serum containing 5% by volume or 10% by volume of the extract obtained in Preparation Example 3 or the enzyme digest solution obtained in Example 4 Replaced with 37 ° C, 5% CO2For 48 hours.
[0054]
Next, after removing the medium and washing with PBS (-), 0.1 N phosphate buffer and 5 mmol L-dopa were added, incubation was performed at 37 ° C. for 1 hour, and the amount of dopachrome produced was measured using a microplate reader. (BIO RAD).
[0055]
The relationship between the amount of extract added or the amount of enzyme hydrolyzate solution added and the amount of dopachrome produced is shown in FIG. 1 (when the extract obtained in Preparation Example 3 is used) and FIG. 3 (obtained in Preparation Example 4). In the case of using an enzymatically decomposed product solution). The graphs in FIGS. 1 and 3 show the amount of dopachrome produced when no extract solution or enzyme solution was added at all as 100%.
[0056]
Further, the amount of the extract added or the amount of the enzyme hydrolyzate solution, and the amount of reduced nicotinamide adenisine dinucleotide (hereinafter referred to as NADH) in mitochondria by the MTT reduction method showing the cell activity of cultured B16 mouse melanoma cells. 2 (in the case of using the extract obtained in Preparation Example 3) and FIG. 4 (in the case of using the enzyme hydrolyzate solution obtained in Preparation Example 4). The graphs in FIGS. 2 and 4 show the amount of NADH in mitochondria by the MTT reduction method assuming that 100% is used when no extract or enzymatic degradation solution is added.
[0057]
As is clear from the graphs shown in FIGS. 1 and 2, the extract obtained in Preparation Example 3 hardly inhibited the cell activity of cultured B16 mouse melanoma cells as the amount of the extract increased, It can be seen that the amount of dopachrome produced is reduced and the intracellular tyrosinase activity is suppressed.
[0058]
Further, as is clear from the graphs shown in FIGS. 3 and 4, the enzyme digest solution obtained in Preparation Example 4 inhibits the cell activity of cultured B16 mouse melanoma cells as the amount added increases. In addition, it was found that the amount of dopachrome produced was significantly reduced, and the intracellular tyrosinase activity was significantly suppressed.
[0059]
Test Example 2 (Melanin production inhibitory action)
10,000 cultured B16 mouse melanoma cells were seeded in a Petri dish (CORNING) having an inner diameter of 60 mm, and cultured at 37 ° C. in 5% CO 2 with Eagle MEM containing 5% by volume of calf serum.2After pre-cultivation for 2 days under the conditions described above, the enzyme digest solution obtained in Preparation Example 4 was replaced with Eagle MEM containing 3% by volume of calf serum supplemented with 5% by volume or 10% by volume, and further at 37 ° C., 5% CO2For 3 days.
[0060]
Next, after removing the medium and washing with PBS (-), the cells are detached with trypsin, the number of cells is counted, and at the same time, high-temperature heat treatment is performed with a 1N aqueous solution of sodium hydroxide containing 10% dimethyl sulfoxide to elute melanin. The solution was then measured for the amount of melanin produced using a variable spectrophotometer (U-2000, manufactured by Hitachi, Ltd.).
[0061]
Enzyme digest solution amount and
[0062]
As is clear from the graph shown in FIG. 5, the enzymatic degradation product solution obtained in Preparation Example 4 significantly inhibits the production of melanin in cultured B16 mouse melanoma cells as the amount added increases. .
[0063]
Test Example 3 (Skin safety)
Using the enzyme hydrolyzate solutions obtained in Preparation Examples 2 and 4, safety on human skin was examined by performing a closed patch test.
[0064]
20 healthy adult males and females aged 20 to 70 years were randomly selected as subjects, and 0.2 ml of the enzyme-decomposed solution obtained in Preparation Example 2 or 4 was applied onto the upper arm skin of each subject. Then, a bandage for human patch test (manufactured by River Tape Co., Ltd.) was applied from above.
[0065]
Further, as a control, the bandage for human patch test was applied so that the circular fabric portions were parallel to the portions to which the enzyme decomposition product solution was applied, respectively.
[0066]
After 48 hours, remove the adhesive patch for each human patch test, visually observe the skin symptoms at the site where the enzyme digest solution was applied and at the control site, and based on the evaluation criteria of the closed patch test by the Japan Patch Test Society. Was evaluated.
[0067]
As a result, no temporary irritation to the human skin of the enzymatically decomposed product solutions obtained in Preparation Examples 2 and 4 was observed, indicating that these enzymatically decomposed product solutions were all excellent in skin safety. .
[0068]
Formulation Examples 1 to 12 and Comparative Formulation Examples 1 to 3
[0069]
Formulation Example 2 (cream)
A cream was prepared in the same manner as in Formulation Example 1, except that the enzyme digest solution obtained in Preparation Example 2 was used instead of the extract solution obtained in Preparation Example 1.
[0070]
Formulation Example 3 (cream)
A cream was prepared in the same manner as in Preparation Example 1, except that the extract obtained in Preparation Example 3 was used instead of the extract obtained in Preparation Example 1.
[0071]
Formulation Example 4 (cream)
A cream was prepared in the same manner as in Formulation Example 1, except that the enzymatic degradation product solution obtained in Preparation Example 4 was used instead of the extract solution obtained in Preparation Example 1.
[0072]
[0073]
[0074]
[0075]
[0076]
[0077]
[0078]
[0079]
[0080]
Comparative prescription example 1 (cream)
A cream was prepared in the same manner as in Formulation Example 1, except that purified water was used instead of the extract obtained in Preparation Example 1.
[0081]
Comparative prescription example 2 (bath agent)
A bath preparation was prepared in the same manner as in Formulation Example 10 except that mannitol (D-mannitol) was used instead of the freeze-dried product obtained in Preparation Example 7.
[0082]
Comparative Prescription Example 3 (Liquid Foundation)
A liquid foundation was prepared in the same manner as in Formulation Example 12, except that purified water was used instead of the enzyme hydrolyzate solution obtained in Preparation Example 4.
[0083]
referenceExample 1
Using the creams obtained in Formulation Example 1 and Comparative Formulation Example 1, the inhibitory effect on pigmentation due to ultraviolet irradiation was examined.
[0084]
Ten healthy adult men aged 20 to 35 years were randomly selected as subjects, and two 1 cm × 1 cm ultraviolet irradiation sections were set on the inner part of the forearm. Using a UV-B lamp (manufactured by Toshiba Corporation, FL20-SE), an ultraviolet ray in an amount corresponding to the minimum erythema dose (MED) of each subject measured in advance once a day (morning) for 3 days Irradiation was continued.
[0085]
For 30 consecutive days from the UV irradiation start date, the UV irradiation period (first 3 days) is immediately after UV irradiation and twice a day in the evening, and after the UV irradiation period (from the 4th day), one day in the morning and evening. Twice, about 0.01 g of the cream obtained in Formulation Example 1 and the cream obtained in Comparative Formulation Example 1 were applied to each UV-irradiated portion.
[0086]
The pigmentation state of the UV-irradiated part of each subject was visually observed every 5 days from the UV-irradiation start date, and the pigmentation-suppressing effect when the cream obtained in Prescription Example 1 was applied was evaluated based on the following evaluation criteria. Was evaluated.
[0087]
(Evaluation criteria)
A: In the place where the cream obtained in Formulation Example 1 was applied, almost no pigmentation was observed.
B: Pigmentation was clearly less at the place where the cream obtained in Formulation Example 1 was applied than at the place where the cream obtained in Comparative Formulation Example 1 was applied.
C: Pigmentation was less at the place where the cream obtained in Formulation Example 1 was applied than at the place where the cream obtained in Comparative Formulation Example 1 was applied.
D: Pigmentation was slightly less at the place where the cream obtained in Formulation Example 1 was applied than at the place where the cream obtained in Comparative Formulation Example 1 was applied.
[0088]
The results of the evaluation of the pigmentation state every five days from the ultraviolet irradiation start date are expressed as a percentage of the number of persons who performed each of the evaluations A to D when 10 subjects were taken as 100%. The results are shown in the graph of FIG.
[0089]
referenceExample 2
referenceIn Example 1, except that the cream obtained in Formulation Example 2 was used instead of the cream obtained in Formulation Example 1,referenceIn the same manner as in Example 1, the pigmentation state of the ultraviolet irradiation part of each subject was evaluated.
[0090]
The evaluation results of the pigmentation state every 5 days from the UV irradiation start date,referenceThe results are shown in the graph of FIG.
[0091]
In addition,referenceIn Examples 1 and 2, when applying the cream obtained in Formulation Examples 1 and 2, none of the subjects had abnormalities on the skin.
[0092]
In addition, the creams obtained in Formulation Examples 1 and 2 did not change their state within 30 days.
[0093]
As is clear from the results shown in FIGS. 6 and 7, regardless of whether the cream obtained in Formulation Example 1 or the cream obtained in Formulation Example 2 was used, from the date of starting the ultraviolet irradiation. As the number of days elapses, the difference in the inhibitory effect on the pigmentation between the case of using the cream obtained in Comparative Formulation Example 1 and the case of using the cream obtained in Comparative Formulation Example 1 increases, and the creams obtained in Formulation Examples 1 and 2 exhibit excellent pigmentation. It can be seen that the effect is obtained.
[0094]
Furthermore, comparing the graph of FIG. 6 and the graph of FIG. 7, when the cream obtained in Prescription Example 2 is used, the occupancy of the A evaluation in which pigmentation is hardly observed is higher, It can be seen that the enzyme hydrolyzate solution obtained in Preparation Example 2 mixed with the cream of Formulation Example 2 exhibits a better pigmentation inhibitory action.
[0095]
Example1
referenceIn Example 1, except that the cream obtained in Formulation Example 3 was used instead of the cream obtained in Formulation Example 1,referenceIn the same manner as in Example 1, the pigmentation state of the ultraviolet irradiation part of each subject was evaluated.
[0096]
The evaluation results of the pigmentation state every 5 days from the UV irradiation start date,referenceThe results are shown in the graph of FIG.
[0097]
referenceAn example3
referenceIn Example 1, except that the cream obtained in Formulation Example 4 was used instead of the cream obtained in Formulation Example 1,referenceIn the same manner as in Example 1, the pigmentation state of the ultraviolet irradiation part of each subject was evaluated.
[0098]
The evaluation results of the pigmentation state every 5 days from the UV irradiation start date,referenceThe results are shown in the graph of FIG.
[0099]
Example1andReference Example 3In the above, none of the subjects had abnormalities on the skin when the creams obtained in Formulation Examples 3 and 4 were applied.
[0100]
In addition, the creams obtained in Formulation Examples 3 and 4 did not change their state within 30 days.
[0101]
As is clear from the results shown in FIGS. 8 and 9, regardless of whether the cream obtained in Formulation Example 3 or the cream obtained in Formulation Example 4 was used, the UV irradiation starting date was not changed. As the number of days elapses, the difference in the inhibitory effect on the pigmentation between the case using the cream obtained in Comparative Formulation Example 1 and the case using the cream obtained in Comparative Formulation Example 1 increases, and the creams obtained in Formulation Examples 3 and 4 show excellent pigmentation. It can be seen that the effect is obtained.
[0102]
Furthermore, comparing the graph of FIG. 8 with the graph of FIG. 9, when the cream obtained in Formulation Example 4 was used, the occupancy of the A evaluation in which pigmentation was hardly observed was extremely high, It can be seen that the enzyme hydrolyzate solution obtained in Preparation Example 4 mixed with the cream of Formulation Example 4 exhibits an extremely excellent pigmentation inhibitory action.
[0103]
Example2
Using the bath preparations obtained in Formulation Example 10 and Comparative Formulation Example 2, the inhibitory effect on the pigmentation of the skin by bathing was examined.
[0104]
A group of 20 healthy adult males and females aged 30 to 60 years were randomly selected and dissolved in 200 liters of hot water, 25 g of each bath preparation, and bathed once a day for one month. The state of pigmentation in the axillary region of each subject group was visually observed, and evaluated based on the following evaluation criteria. Table 1 shows the results.
[0105]
(Evaluation criteria)
A: Almost no pigmentation was observed.
B: Pigmentation was clearly reduced.
C: Pigmentation was less than before using the bath agent.
D: There is almost no change from before using the bath agent.
E: Pigmentation rather increased than before using the bath agent.
[0106]
[Table 1]
As is evident from the results shown in Table 1, when the bath preparation obtained in Preparative Example 10 was used, the pigmentation almost disappeared or became less, so that the bath preparation obtained in Comparative Preparative Example 2 was used. It can be seen that the agent can hardly suppress pigmentation, whereas the bath agent obtained in Prescription Example 10 exhibits an excellent pigmentation inhibiting effect.
[0108]
Example2In, when taking a bath using the bath preparation obtained in Prescription Example 10, none of the subjects had abnormal skin or the like.
[0109]
The condition of the bath preparation obtained in Formulation Example 10 did not change within one month.
[0110]
referenceAn example4
Using the liquid foundations obtained in Formulation Example 12 and Comparative Formulation Example 3, the effect of improving dullness was examined.
[0111]
Forty healthy adult women aged 25 to 35 years were randomly selected as subjects, and the liquid foundation obtained in Formulation Example 12 on the right cheek of each subject was obtained in Comparative Formulation Example 3 on the left cheek of the face. The liquid foundation was applied once a day for one month for a normal amount (approximately 0.1 g), and the left and right cheeks were visually observed and compared. It was evaluated based on:
[0112]
(Evaluation criteria)
A: The right cheek was significantly less dull.
B: The right cheek was clearly less dull.
C: The right cheek has a little less dullness.
D: No difference is observed between the right and left cheeks.
E: The left cheek was clearly less dull.
[0113]
As a result, there were 19 subjects having A evaluation, 20 subjects having B evaluation and 1 subject having C evaluation, none of the subjects having given D evaluation and E evaluation, and the liquid foundation obtained in Formulation Example 12 was used. Ai shows that the liquid foundation obtained in Prescription Example 12 has an excellent effect of improving the dullness because the dullness is reduced as compared with the case where the liquid foundation obtained in Comparative Prescription Example 3 is used. You can see that.
[0114]
In addition,referenceAn example4In the above, none of the subjects had abnormalities on the skin when the liquid foundation obtained in Prescription Example 12 was applied.
[0115]
In addition, the liquid foundation obtained in Prescription Example 12 did not change its condition within one month.
[0116]
【The invention's effect】
Refined grain residueRice branThe extract obtained by extracting with a neutral medium suppresses the melanin production by decreasing the cell activity of the cultured pigment cells, which is an indicator of the whitening effect, with little inhibition of the cell activity. Since it simultaneously exhibits an excellent effect of suppressing pigmentation caused by ultraviolet irradiation, the whitening cosmetic of the present invention containing such an extract suppresses the appearance of spots and freckles due to accumulation of melanin, It has the effect of improving the condition of the skin and maintaining beautiful white skin with improved dullness.
[0118]
In addition, the whitening cosmetic of the present invention has an excellent whitening effect as described above, and also has an effect of being excellent in safety against skin and the like and storage stability.
[Brief description of the drawings]
FIG. 1 is a graph showing the relationship between the amount of extract added in Preparation Example 3 and the amount of dopachrome produced.
FIG. 2 is a graph showing the relationship between the amount of extract added in Preparation Example 3 and the amount of NADH in mitochondria by the MTT reduction method.
FIG. 3 is a graph showing the relationship between the amount of an enzyme hydrolyzate solution obtained in Preparation Example 4 and the amount of dopachrome produced.
FIG. 4 is a graph showing the relationship between the amount of an enzyme hydrolyzate solution obtained in Preparation Example 4 and the amount of NADH in mitochondria by the MTT reduction method.
FIG. 5 shows the amount of the enzyme hydrolyzate solution obtained in Preparation Example 4 and the amount of
FIG. 6 is a graph showing the temporal change in the occupancy of each evaluation of the pigmentation-suppressing effect when the cream obtained in Formulation Example 1 is applied from the ultraviolet irradiation start date.
FIG. 7 is a graph showing the change over time in the occupancy of each evaluation of the pigmentation inhibitory effect when the cream obtained in Formulation Example 2 is applied from the ultraviolet irradiation start date.
FIG. 8 is a graph showing the temporal change in the occupancy of each evaluation of the pigmentation inhibitory effect when the cream obtained in Formulation Example 3 is applied from the ultraviolet irradiation start date.
FIG. 9 is a graph showing the time-dependent change in the occupancy of each evaluation of the pigmentation-suppressing effect when the cream obtained in Prescription Example 4 is applied from the ultraviolet irradiation start date.
Claims (3)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP09531994A JP3576200B2 (en) | 1994-05-09 | 1994-05-09 | Whitening cosmetics |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP09531994A JP3576200B2 (en) | 1994-05-09 | 1994-05-09 | Whitening cosmetics |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003350708A Division JP3818998B2 (en) | 2003-10-09 | 2003-10-09 | Whitening cosmetics |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH07304648A JPH07304648A (en) | 1995-11-21 |
| JP3576200B2 true JP3576200B2 (en) | 2004-10-13 |
Family
ID=14134432
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP09531994A Expired - Lifetime JP3576200B2 (en) | 1994-05-09 | 1994-05-09 | Whitening cosmetics |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP3576200B2 (en) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3499336B2 (en) * | 1995-09-21 | 2004-02-23 | 株式会社テクノーブル | Anti-aging cosmetics |
| JPH09255526A (en) * | 1996-03-27 | 1997-09-30 | Shiseido Co Ltd | Anti-aging cosmetics |
| JPH09301818A (en) * | 1996-05-14 | 1997-11-25 | Kao Corp | Skin lotion |
| JP3635423B2 (en) * | 1997-01-14 | 2005-04-06 | 株式会社カネボウ化粧品 | Skin cosmetics |
| JPH11116435A (en) * | 1997-10-06 | 1999-04-27 | Nitto Denko Corp | Whitening cosmetic sheet and method of using the same |
| JP3936808B2 (en) * | 1998-07-29 | 2007-06-27 | 共栄化学工業株式会社 | How to reduce skin irritation |
| JP2000044459A (en) * | 1998-07-29 | 2000-02-15 | Tekunooburu:Kk | Skin preparation for external use |
| JP2000119160A (en) * | 1998-10-06 | 2000-04-25 | Kanebo Ltd | Skin cosmetic |
| JP2000351722A (en) * | 1999-06-07 | 2000-12-19 | Tekunooburu:Kk | Skin cosmetic |
| JP2001026530A (en) * | 1999-07-12 | 2001-01-30 | Oriza Yuka Kk | Whitening agent |
| JP3502808B2 (en) * | 2000-04-26 | 2004-03-02 | 石川県 | Cosmetics |
| JP4500906B2 (en) * | 2001-01-31 | 2010-07-14 | 共栄化学工業株式会社 | Cosmetic compounding agent and cosmetics containing the same |
| JP2002255784A (en) * | 2001-03-02 | 2002-09-11 | Oriza Yuka Kk | Composition for beautiful skin |
| JP2002284625A (en) * | 2001-03-23 | 2002-10-03 | Nippon Hypox Lab Inc | Cosmetics |
| JP4025600B2 (en) * | 2002-08-12 | 2007-12-19 | 山川貿易株式会社 | Topical skin preparation |
| KR100544831B1 (en) * | 2003-06-17 | 2006-01-24 | 한불화장품주식회사 | Cosmetic composition containing peptide mixture hydrolyzed with germinated black soybean and black rice protease |
| JP2005015450A (en) * | 2003-06-30 | 2005-01-20 | Kanebo Cosmetics Inc | Skin cosmetics |
| JP4573545B2 (en) * | 2004-03-11 | 2010-11-04 | 共栄化学工業株式会社 | Cosmetics |
| JP2007217324A (en) * | 2006-02-15 | 2007-08-30 | Soken Kk | Whitening agent and internal or external composition containing the same |
| JP6158147B2 (en) * | 2014-08-04 | 2017-07-05 | 株式会社創研 | Whitening agent and internal or external composition containing the same |
| JP6533478B2 (en) * | 2016-02-29 | 2019-06-19 | 株式会社創研 | Whitening agent and internal or external composition containing the same |
| JP2021024805A (en) * | 2019-08-05 | 2021-02-22 | 共栄化学工業株式会社 | External preparation for skin |
| CN113116778B (en) * | 2021-04-16 | 2022-03-08 | 广州中草世家化妆品有限公司 | Ginseng extracting solution and preparation method and application thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0615450B2 (en) * | 1987-04-08 | 1994-03-02 | 一丸フアルコス株式会社 | Moisturizing ingredient for blending cosmetics consisting of gluten hydrolyzed extract |
| JP3040440B2 (en) * | 1990-09-06 | 2000-05-15 | 株式会社創研 | Skin improver |
| JP3171637B2 (en) * | 1992-02-17 | 2001-05-28 | 共栄化学工業株式会社 | Anti-aging cosmetics |
-
1994
- 1994-05-09 JP JP09531994A patent/JP3576200B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JPH07304648A (en) | 1995-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3576200B2 (en) | Whitening cosmetics | |
| JP3171637B2 (en) | Anti-aging cosmetics | |
| KR100552329B1 (en) | Cosmetics | |
| JP6266857B2 (en) | Cosmetics | |
| JP3601875B2 (en) | Cosmetics | |
| JP5937786B2 (en) | Marine organism-derived collagen containing type III collagen and derivatives thereof | |
| JP3936808B2 (en) | How to reduce skin irritation | |
| JP4424561B2 (en) | Whitening cosmetics | |
| JP3846680B2 (en) | Cosmetics | |
| JP6704628B2 (en) | Cosmetics | |
| JP3818998B2 (en) | Whitening cosmetics | |
| JP4592911B2 (en) | Cosmetics | |
| JP4573545B2 (en) | Cosmetics | |
| JP4824933B2 (en) | Cosmetics | |
| JP3044690B2 (en) | Cosmetics | |
| JP4621958B2 (en) | Cosmetic compounding agent and cosmetics containing the same | |
| JP3635423B2 (en) | Skin cosmetics | |
| JP2005145938A (en) | Active oxygen scavenger and cosmetic | |
| JP4445658B2 (en) | Cosmetics | |
| JP4500906B2 (en) | Cosmetic compounding agent and cosmetics containing the same | |
| JP2000044459A (en) | Skin preparation for external use | |
| JP2003238429A (en) | Fibroblast cell-activating agent and skin external agent containing the same | |
| JPH09175980A (en) | Cosmetic | |
| JP6725203B2 (en) | Cosmetics | |
| JP2963136B2 (en) | Cosmetics |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20031104 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20031226 |
|
| A911 | Transfer of reconsideration by examiner before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20040415 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20040322 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20040608 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20040707 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100716 Year of fee payment: 6 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130716 Year of fee payment: 9 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| EXPY | Cancellation because of completion of term |